BioNTech bags Instadeep for £562m
BioNTech SE will pay £562m in cash to acquire its former partner InstaDeep Ltd. to expand its capabilities in AI-based drug discovery.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
At the interface of AI, healthcare, and data science
The AI Health Innovation Cluster is bringing together leading scientists at the interface
of artificial intelligence (AI), healthcare, and data science. The goal is to combine and further develop the outstanding research networks and infrastructures in modern health data sciences that have emerged in the Rhine-Neckar region in Germany in recent years.
Roche withdraws checkpoint blocker from the market
Roche AGs US subsidiary Genentech Inc has withdrawn its checkpoint inhibitor atezolizumab from the market after disappointing results in bladder cancer.
Lessons learned in the face of new health challenges
SARS-COV-2 exposed our vulnerability and strategic weakness at European level, in terms of biotechnological manufacturing capacity.
ExeVir receives EIB risk finance for multiple COVID-19 nanobody
With the help of a €25m loan from the European Investment Bank, ExeVir BIO BV will advance clinical trials with its COVID-19 nanobody XVR012.
Hummingbird and Synaffix in $150m ADC deal
Rational antibody design specialist Hummingbird Bioscience has licenced a cancer target and the modular ADC technology of Dutch Synaffix BV.
Ethris inks €15m deal with Indian Ciplas
Cipla EU Ltd is going to make an equity investment of €15m in Ethris GmbH, a specialist for respiratory delivery of therapeutic mRNAs.
First hints for leukopenia diagnostic in MS
Scientists from the University of Basel and the University Hospital Basel have found that two bacterial species may indicate multiple sclerosis-associated lymphopenia.
Innate immunity and its power in cancer therapy
One of the most distinguishing hallmarks of tumours is their ability to avoid immune recognition. New immunotherapies have focused on breaking down those barriers, leading to treatment breakthroughs for blood cancers. While these therapies have shown great promise for some indications, we still lack effective therapies for many others. A novel route to address this is to the restore innate immunitys ability to fight cancer.
Numares AG cashes in €20m from EIB
The European Investment Bank (EIB) is going to support the AI-platform of NMR/metabolomics diagnostics company Numares AG to improve disease prediction.